Cellio Therapeutics

Cellio Therapeutics is a private biotechnology company focused on the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company leverages a deep understanding of immune system pathways to create targeted small molecule treatments designed to improve patient outcomes. Led by a team of industry veterans, including CEO Michael Howell, the company is building a pipeline of programs aimed at high-value indications with significant unmet needs. Cellio's approach integrates advanced biological insights with efficient drug discovery to identify next-generation candidates. The firm is backed by prominent life science investors such as Fairmount and Venrock.